Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Get Free Report) COO Eben Tessari sold 12,000 shares of Kiniksa Pharmaceuticals stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $20.48, for a total value of $245,760.00. Following the completion of the transaction, the chief operating officer now owns 77,363 shares of the company's stock, valued at $1,584,394.24. The trade was a 13.43 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
Eben Tessari also recently made the following trade(s):
- On Monday, February 10th, Eben Tessari sold 14,000 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $19.57, for a total transaction of $273,980.00.
Kiniksa Pharmaceuticals Stock Down 3.3 %
KNSA opened at $20.53 on Thursday. The firm has a market cap of $1.49 billion, a price-to-earnings ratio of -146.63 and a beta of 0.31. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $16.56 and a 52 week high of $28.15. The business's 50 day moving average is $21.03 and its two-hundred day moving average is $21.56.
Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The business had revenue of $122.50 million during the quarter, compared to analysts' expectations of $123.42 million. During the same quarter last year, the company earned $0.35 EPS. The firm's revenue for the quarter was up 46.9% compared to the same quarter last year. Equities analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current fiscal year.
Hedge Funds Weigh In On Kiniksa Pharmaceuticals
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Braidwell LP grew its stake in shares of Kiniksa Pharmaceuticals by 19.3% in the 4th quarter. Braidwell LP now owns 3,452,447 shares of the company's stock valued at $68,289,000 after purchasing an additional 557,934 shares during the last quarter. Nuveen Asset Management LLC lifted its holdings in shares of Kiniksa Pharmaceuticals by 7.3% during the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after purchasing an additional 54,361 shares during the period. Millennium Management LLC grew its position in Kiniksa Pharmaceuticals by 50.9% in the 4th quarter. Millennium Management LLC now owns 779,672 shares of the company's stock valued at $15,422,000 after buying an additional 263,146 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Kiniksa Pharmaceuticals by 3.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 771,607 shares of the company's stock valued at $15,262,000 after buying an additional 29,300 shares during the period. Finally, Parkman Healthcare Partners LLC raised its position in Kiniksa Pharmaceuticals by 1.4% during the 4th quarter. Parkman Healthcare Partners LLC now owns 765,453 shares of the company's stock worth $15,141,000 after buying an additional 10,209 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company's stock.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on KNSA shares. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a "buy" rating and a $40.00 price objective on the stock. Wedbush restated an "outperform" rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research report on Wednesday. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Kiniksa Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $37.17.
Get Our Latest Stock Report on Kiniksa Pharmaceuticals
About Kiniksa Pharmaceuticals
(
Get Free Report)
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
